Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach - PubMed (original) (raw)
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach
K S Bankiewicz et al. Exp Neurol. 2000 Jul.
Abstract
Using an approach that combines gene therapy with aromatic l-amino acid decarboxylase (AADC) gene and a pro-drug (l-dopa), dopamine, the neurotransmitter involved in Parkinson's disease, can be synthesized and regulated. Striatal neurons infected with the AADC gene by an adeno-associated viral vector can convert peripheral l-dopa to dopamine and may therefore provide a buffer for unmetabolized l-dopa. This approach to treating Parkinson's disease may reduce the need for l-dopa/carbidopa, thus providing a better clinical response with fewer side effects. In addition, the imbalance in dopamine production between the nigrostriatal and mesolimbic dopaminergic systems can be corrected by using AADC gene delivery to the striatum. We have also demonstrated that a fundamental obstacle in the gene therapy approach to the central nervous system, i.e., the ability to deliver viral vectors in sufficient quantities to the whole brain, can be overcome by using convection-enhanced delivery. Finally, this study demonstrates that positron emission tomography and the AADC tracer, 6-[(18)F]fluoro-l-m-tyrosine, can be used to monitor gene therapy in vivo. Our therapeutic approach has the potential to restore dopamine production, even late in the disease process, at levels that can be maintained during continued nigrostriatal degeneration.
Copyright 2000 Academic Press.
Similar articles
- Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
Ciesielska A, Samaranch L, San Sebastian W, Dickson DW, Goldman S, Forsayeth J, Bankiewicz KS. Ciesielska A, et al. PLoS One. 2017 Feb 6;12(2):e0169965. doi: 10.1371/journal.pone.0169965. eCollection 2017. PLoS One. 2017. PMID: 28166239 Free PMC article. - Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.
Bankiewicz KS, Daadi M, Pivirotto P, Bringas J, Sanftner L, Cunningham J, Forsayeth JR, Eberling JL. Bankiewicz KS, et al. Exp Neurol. 2006 Feb;197(2):363-72. doi: 10.1016/j.expneurol.2005.10.022. Epub 2005 Dec 9. Exp Neurol. 2006. PMID: 16337943 Free PMC article. - Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Sánchez-Pernaute R, Harvey-White J, Cunningham J, Bankiewicz KS. Sánchez-Pernaute R, et al. Mol Ther. 2001 Oct;4(4):324-30. doi: 10.1006/mthe.2001.0466. Mol Ther. 2001. PMID: 11592835 - [AAV vector-mediated gene transfer and its application to the nervous system].
Ozawa K. Ozawa K. Rinsho Shinkeigaku. 2003 Nov;43(11):835-8. Rinsho Shinkeigaku. 2003. PMID: 15152479 Review. Japanese. - Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain.
Cederfjäll E, Sahin G, Kirik D. Cederfjäll E, et al. Neurobiol Dis. 2012 Nov;48(2):222-7. doi: 10.1016/j.nbd.2011.10.017. Epub 2011 Oct 25. Neurobiol Dis. 2012. PMID: 22048069 Review.
Cited by
- In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastoma.
Liu SJ, Zou C, Pak J, Morse A, Pang D, Casey-Clyde T, Borah AA, Wu D, Seo K, O'Loughlin T, Lim DA, Ozawa T, Berger MS, Kamber RA, Weiss WA, Raleigh DR, Gilbert LA. Liu SJ, et al. Genome Biol. 2024 Oct 7;25(1):256. doi: 10.1186/s13059-024-03404-6. Genome Biol. 2024. PMID: 39375777 Free PMC article. - Neurosurgical gene therapy for central nervous system diseases.
Patel RV, Nanda P, Richardson RM. Patel RV, et al. Neurotherapeutics. 2024 Jul;21(4):e00434. doi: 10.1016/j.neurot.2024.e00434. Epub 2024 Aug 26. Neurotherapeutics. 2024. PMID: 39191071 Free PMC article. Review. - In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification.
Ebrahimi P, Davoudi E, Sadeghian R, Zadeh AZ, Razmi E, Heidari R, Morowvat MH, Sadeghian I. Ebrahimi P, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Oct;397(10):7501-7530. doi: 10.1007/s00210-024-03141-4. Epub 2024 May 22. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38775852 Review. - An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys.
Liang L, Zimmermann Rollin I, Alikaya A, Ho JC, Santini T, Bostan AC, Schwerdt HN, Stauffer WR, Ibrahim TS, Pirondini E, Schaeffer DJ. Liang L, et al. J Neurosci Methods. 2024 Jul;407:110133. doi: 10.1016/j.jneumeth.2024.110133. Epub 2024 Apr 6. J Neurosci Methods. 2024. PMID: 38588922 - Taking the knife to neurodegeneration: a review of surgical gene therapy delivery to the CNS.
Perera A, Brock O, Ahmed A, Shaw C, Ashkan K. Perera A, et al. Acta Neurochir (Wien). 2024 Mar 14;166(1):136. doi: 10.1007/s00701-024-06028-8. Acta Neurochir (Wien). 2024. PMID: 38483631 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical